Thumbnail Image
Publication

Drug Pricing Investigation: Teva--Copaxone

House Committee on Oversight and Reform
Abstract
Teva raised Copaxone's price 27 times since its launch in 1997, resulting in a yearly course costing nearly $70,000, compared to less than $10,000 in 1997. Teva's price increases contributed to over $34 billion in Copaxone net U.S. revenue, accompanied by millions in executive compensation. The report concludes that structural reforms, such as Medicare negotiation, are essential to address the pharmaceutical industry's pricing practices.
Date
2020-09-30
Document Type
House Staff Report
Serial Number
Document Length
55 pages
Congress
116
Show all metadata
Files
Thumbnail Image
2020-09-30_R-Drug_Pricing_Investigation-(Teva-Copaxone)-116C.pdf
Adobe PDF, 2.08 MB
Thumbnail Image
2020-09-30_R-Teva-Copaxone-(selected_docs)-116C.pdf
Adobe PDF, 5.56 MB
URI
https://hdl.handle.net/20.500.14300/1169
Relation
DOI
Keywords
Staff Reports
PAP Major Code
3: Health
PAP Minor Code
335: Prescription Drug Coverage and Costs
Related Hearings
Press Releases and Contextual Information
Collections
House Oversight Committee